FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167081024> ?p ?o ?g. }

• W3167081024 endingPage "e16114" @default.
• W3167081024 startingPage "e16114" @default.
• W3167081024 abstract "e16114 Background: Transcatheter arterial chemoembolization (TACE) is considered to be the first-line topical therapy for unresectable hepatocellular carcinoma (HCC). However, the long-term efficacy of single TACE treatment is poor, with a five-year survival rate of 8%-43%. This study aims to investigate the efficacy and safety of TACE combined with camrelizumab in the treatment of unresectable HCC. Methods: This is a single-arm, prospective real-word study conducted in 14 hospitals in Jiangsu, China. Patients diagnosed with HCC received Camrelizumab (200mg, i.v. Q2W or Q3W) with or without antiangiogenic therapy (apatinib, lenvatinib, sorafenib, or regorafenib) at any stage of the TACE treatment. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Kaplan-Meier method was used for survival analysis. This study was registered with ChiCTR.org.cn, number ChiCTR1900026163. Results: From September 2019 to January 2021, 151 patients were enrolled, of whom most were males and younger than 65 years, 92 (60.93%) had extrahepatic metastasis and 120 (79.47%) suffered from HBV infection, 59 (39.07%) had an AFP concentration of 400 ng/mL or higher, 150 (99.34) had an ECOG PS of 0 or 1, a Child-Puph score of A or B, and were classified as BCLC Stage B or C. In addition to TACE, 52 patients received camrelizumab alone, while the others also received antiangiogenic therapy. Most (139, 92.06%) of the patients received camrelizumab 200mg every 3 weeks. Of the 112 patients who were available for efficacy evaluation, 4 patients achieved CR, 25 achieved PR, and 53 achieved SD, resulting in an ORR of 25.89% and DCR of 73.21%. The median PFS was 4.27 months (95% CI, 3.45 to 7.36 months) and the median OS was 14.0 months (95% CI, 10.6 to NE months). The safety data were obtained from 140 patients. Treatment-related adverse events (TRAEs) occurred in 130 (92.86%) patients, with the commonest types including increased alanine and aspartate aminotransferases (65%), thrombocytopenia (57.86%), hypoalbuminemia (54.29%), hyperbilirubinemia (48.57%), anemia (42.86%), leukopenia (42.14%), neutropenia (37.14%) and proteinuria (20.71%). Severe AEs occurred in 52 (37.14%) patients, with the commonest types including thrombocytopenia (17.14%), increased alanine and aspartate aminotransferases (13.57%), neutropenia (8.57%) and hyperbilirubinemia (7.14%). Conclusions: The treatment strategy of TACE in combination with camrelizumab with or without antiangiogenic therapy showed encouraging clinical efficacy and manageable toxicity profile in treating unresectable HCC, which provided a new treatment option for HCC. Clinical trial information: ChiCTR1900026163." @default.
• W3167081024 created "2021-06-22" @default.
• W3167081024 creator A5002559594 @default.
• W3167081024 creator A5005478064 @default.
• W3167081024 creator A5010442064 @default.
• W3167081024 creator A5021499700 @default.
• W3167081024 creator A5032278821 @default.
• W3167081024 creator A5041606347 @default.
• W3167081024 creator A5052098657 @default.
• W3167081024 creator A5060418827 @default.
• W3167081024 creator A5071717993 @default.
• W3167081024 creator A5077397027 @default.
• W3167081024 creator A5083340325 @default.
• W3167081024 creator A5087492061 @default.
• W3167081024 date "2021-05-20" @default.
• W3167081024 modified "2023-09-27" @default.
• W3167081024 title "Camrelizumab in combination with TACE for the treatment of unresectable hepatocellular carcinoma (HCC): A multicenter, single-arm, prospective real-world study." @default.
• W3167081024 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e16114" @default.
• W3167081024 hasPublicationYear "2021" @default.
• W3167081024 type Work @default.
• W3167081024 sameAs 3167081024 @default.
• W3167081024 citedByCount "2" @default.
• W3167081024 countsByYear W31670810242022 @default.
• W3167081024 crossrefType "journal-article" @default.
• W3167081024 hasAuthorship W3167081024A5002559594 @default.
• W3167081024 hasAuthorship W3167081024A5005478064 @default.
• W3167081024 hasAuthorship W3167081024A5010442064 @default.
• W3167081024 hasAuthorship W3167081024A5021499700 @default.
• W3167081024 hasAuthorship W3167081024A5032278821 @default.
• W3167081024 hasAuthorship W3167081024A5041606347 @default.
• W3167081024 hasAuthorship W3167081024A5052098657 @default.
• W3167081024 hasAuthorship W3167081024A5060418827 @default.
• W3167081024 hasAuthorship W3167081024A5071717993 @default.
• W3167081024 hasAuthorship W3167081024A5077397027 @default.
• W3167081024 hasAuthorship W3167081024A5083340325 @default.
• W3167081024 hasAuthorship W3167081024A5087492061 @default.
• W3167081024 hasConcept C121608353 @default.
• W3167081024 hasConcept C126322002 @default.
• W3167081024 hasConcept C141071460 @default.
• W3167081024 hasConcept C143998085 @default.
• W3167081024 hasConcept C146357865 @default.
• W3167081024 hasConcept C151730666 @default.
• W3167081024 hasConcept C203092338 @default.
• W3167081024 hasConcept C2776248978 @default.
• W3167081024 hasConcept C2776264508 @default.
• W3167081024 hasConcept C2776283816 @default.
• W3167081024 hasConcept C2776694085 @default.
• W3167081024 hasConcept C2778019345 @default.
• W3167081024 hasConcept C2778695046 @default.
• W3167081024 hasConcept C2779984678 @default.
• W3167081024 hasConcept C2780739268 @default.
• W3167081024 hasConcept C31760486 @default.
• W3167081024 hasConcept C526805850 @default.
• W3167081024 hasConcept C535046627 @default.
• W3167081024 hasConcept C71924100 @default.
• W3167081024 hasConcept C86803240 @default.
• W3167081024 hasConcept C90924648 @default.
• W3167081024 hasConceptScore W3167081024C121608353 @default.
• W3167081024 hasConceptScore W3167081024C126322002 @default.
• W3167081024 hasConceptScore W3167081024C141071460 @default.
• W3167081024 hasConceptScore W3167081024C143998085 @default.
• W3167081024 hasConceptScore W3167081024C146357865 @default.
• W3167081024 hasConceptScore W3167081024C151730666 @default.
• W3167081024 hasConceptScore W3167081024C203092338 @default.
• W3167081024 hasConceptScore W3167081024C2776248978 @default.
• W3167081024 hasConceptScore W3167081024C2776264508 @default.
• W3167081024 hasConceptScore W3167081024C2776283816 @default.
• W3167081024 hasConceptScore W3167081024C2776694085 @default.
• W3167081024 hasConceptScore W3167081024C2778019345 @default.
• W3167081024 hasConceptScore W3167081024C2778695046 @default.
• W3167081024 hasConceptScore W3167081024C2779984678 @default.
• W3167081024 hasConceptScore W3167081024C2780739268 @default.
• W3167081024 hasConceptScore W3167081024C31760486 @default.
• W3167081024 hasConceptScore W3167081024C526805850 @default.
• W3167081024 hasConceptScore W3167081024C535046627 @default.
• W3167081024 hasConceptScore W3167081024C71924100 @default.
• W3167081024 hasConceptScore W3167081024C86803240 @default.
• W3167081024 hasConceptScore W3167081024C90924648 @default.
• W3167081024 hasIssue "15_suppl" @default.
• W3167081024 hasLocation W31670810241 @default.
• W3167081024 hasOpenAccess W3167081024 @default.
• W3167081024 hasPrimaryLocation W31670810241 @default.
• W3167081024 hasRelatedWork W2060982698 @default.
• W3167081024 hasRelatedWork W2558335336 @default.
• W3167081024 hasRelatedWork W2914412589 @default.
• W3167081024 hasRelatedWork W2933348020 @default.
• W3167081024 hasRelatedWork W2953504750 @default.
• W3167081024 hasRelatedWork W2996066981 @default.
• W3167081024 hasRelatedWork W3009513461 @default.
• W3167081024 hasRelatedWork W3086685948 @default.
• W3167081024 hasRelatedWork W3167081024 @default.
• W3167081024 hasRelatedWork W4210681122 @default.
• W3167081024 hasVolume "39" @default.
• W3167081024 isParatext "false" @default.
• W3167081024 isRetracted "false" @default.
• W3167081024 magId "3167081024" @default.
• W3167081024 workType "article" @default.